

APPLICATION OF CARBON-13
IN BIOSYNTHETIC STUDIES; FT-¹³C
NUCLEAR MAGNETIC
RESONANCE SPECTRA OF
DIHYDROLATUMCIDIN

Sir:

The advantage of biosynthetic studies conducted on microbial metabolites, which utilize carbon-13 precursors in combination with FT cmr *versus* those with carbon-14 tracers have been previously noted¹.

The antibiotic latumcidin²⁾ (abikoviromycin)³⁾ produced by *Streptomyces reticuli* var. *latumcidicus* would be a metabolite of choice to be studied with carbon-13 precursors, since it seems to be biosynthesized from acetate *via* a polyketide as shown in Fig. 1.

Latumcidin separately labeled with either CH₃¹³COONa or ¹³CH₃COONa was reduced with NaBH₄³⁾ to a relatively stable derivative, dihydrolatumcidin in order to overcome the difficulty caused by the decomposition of latumcidin during isolation. The reduction product, consisting of only one isomer, was proven to be

identical with naturally occurring dihydrolatumcidin, the intermediacy of which had been verified by its enzymatic conversion to latumcidin⁴⁾.

The cmr spectrum of dihydrolatumcidin labeled with CH₃¹³COONa (see Fig. 2) exhibited five enhanced peaks assignable⁵⁾ to C-2, 4, 6, 7a and 8 while peaks C-3, 4a, 5, 7 and 9 were considerably weaker. On the other hand, the reversal of the signal intensity is evident in the spectrum (Fig. 3) obtained from ¹³CH₃COONa labeling experiment. The following peaks were assigned unambiguously by the aid of off-resonance and selective proton decoupling experiments; δ_{C}^{TMS} 14.0(C-9), 25.9(C-3), 39.6(C-2), 59.2(C-4), 63.1(C-7a), 64.1(C-4a), 114.9(C-8), 131.7(C-6), 133.8(C-7) and 140.0(C-5). It should be noted that the C-C coupling ($J=57$ Hz) between 4a and 5 observed is in agreement with the previous assignments.

These results clearly indicate that latumcidin is biosynthesized from five acetate units as shown in Fig. 1.

The incorporation ratio was determined by the direct comparison of the signal intensities

Fig. 1. Biogenetic pathway of latumcidin




Fig. 2. Proton noise decoupled FT-cmr spectrum of dihydrolatumcidin in CDCl₃ from CH₃¹³COONa (56 atom %), 112 mg. The spectrum was taken at 25.5 MHz on a Varian XL-100 spectrometer. pulse width = 25 μ sec; acquisition time = 0.8 sec; 1,000 transients.




Fig. 3. Proton noise decoupled FT-cmr spectrum of dihydrolatumcidin in CDCl_3 from $^{13}\text{CH}_3\text{COONa}$ (61 atom %), 79 mg. Other data are same as in Fig. 2.





Fig. 4. Proton noise decoupled FT-cmr spectrum of unlabeled dihydrolatumcidin. 34,000 transients.



of C_8 and C_7 in the cmr spectra of the labeled samples, since the intensities of these two peaks in the spectrum of the unlabeled sample are completely same (Fig. 4). The values obtained are 17.3% for the sample labeled with $\text{CH}_3^{13}\text{COONa}$ and 6.6% for the sample labeled with $^{13}\text{CH}_3\text{COONa}$.

Although the cyclization mechanism remains to be studied, it seems likely that latumcidin can be formed through a mechanism similar to that involved in the biosynthesis of brefeldin A⁶⁾.

Support of this work by the Mitsubishi Foundation is acknowledged. We thank Dr. M. TANABE of Stanford Research Institute for his kind advice.

HARUO SETO
TSUTOMU SATO
HIROSHI YONEHARA

Institute of Applied Microbiology,
University of Tokyo
Bunkyo-ku, Tokyo, Japan

WILLIAM C. JANKOWSKI

Analytical Instrument Division,
Varian Associates,
Palo Alto, California 94303, U.S.A.

(Received May 14, 1973)

References

- 1) TANABE, M.; H. SETO & L. F. JOHNSON: Biosynthetic studies with carbon-13. Carbon-13 nuclear magnetic resonance spectra of radicinin. *J. Amer. Chem. Soc.* 92: 2157~2158, 1970; TANABE, M.; T. HAMASAKI, H. SETO & L. F. JOHNSON: Biosynthetic studies with carbon-13: ^{13}C nuclear magnetic resonance spectra of the metabolite sterigmatocystin. *Chem. Comm.* 1539~1540, 1970; TANABE, M.; T. HAMASAKI & L. F. JOHNSON: Biosynthetic studies with carbon-13: asperlin. *J. Amer. Chem. Soc.* 93: 273~274, 1971; WESTLEY, J. W.; D. L. PRUESS & R. G. FITCHER: Incorporation of $[1-^{13}\text{C}]$ butyrate into antibiotic X-537A: ^{13}C nuclear magnetic resonance study, *Chem. Comm.* 161~162, 1972; CUSHLEY, R. J.; D. R. ANDERSON,

- S. R. LIPSKY, R. J. SYKES & H. H. WASSERMAN: Carbon-13 fourier transform nuclear magnetic resonance spectroscopy. II. The pattern of biosynthetic incorporation of [1-¹³C] -and [2-¹⁸C] acetate into prodigiosin. *J. Amer. Chem. Soc.* 93: 6284~6286, 1971; IAN SCOTT, A.; C. A. TOWNSEND, K. OKADA, M. KAJIWARA, P. J. WHITMAN & R. J. CUSHLEY: Biosynthesis of corrinoids. Concerning the origin of the methyl groups in vitamin B₁₂. *J. Amer. Chem. Soc.* 94: 8267~8269, 1972
- 2) SAKAGAMI, Y.; I. YAMAGUCHI, H. YONEHARA, Y. OKIMOTO, S. YAMANOUCHI, K. TAKIGUCHI & H. SAKAI: Latumcidin, a new antibiotic from *Streptomyces* sp. *J. Antibiotics, Ser. A* 11: 6~13, 1958; KŌNO, Y.; S. TAKEUCHI, H. YONEHARA, F. MARUMO & Y. SAITO: The crystal and molecular structure of latumcidin selenate. *Acta Cryst. B* 27: 2341~2345, 1971
- 3) UMEZAWA, H.; T. TAZAKI & S. FUKUYAMA: An antiviral substance, abikoviromycin, produced by *Streptomyces* species. *J. Antibiotics* 5: 469~476, 1952; GUREVICH, A. I.; M. N. KOROSOV, V. G. KOROBKO & V. V. ONOPRIENKO: The structure of abikoviromycin. *Tetrahedron Letters* 1968: 2209~2212, 1968
- 4) OGAWA, Y.; T. TSURUOKA, T. SHŌMURA, H. WATANABE, S. INOUE & T. NIIDA: *J. Antibiotics* 26: 186~188, 1973
- 5) STOTHERS, J. B.: Carbon-13 nmr spectroscopy. Academic Press, New York and London, 1972, LEVY, G. C. & G. L. NELSON: Carbon-13 nuclear magnetic resonance for organic chemists, Wiley-Interscience, New York, 1972
- 6) HANDSCHIN, U.; H. P. SIGG & CH. TAMM: Zur biosynthese von Brefeldin A. *Helv. Chim. Acta* 51: 1943~1965, 1968